DIA Biosimilars 2013

inVentiv Health

inVentiv launches company to consolidate European services

Thursday, August 25, 2011 01:53 PM

inVentiv Health will encompass advertising, PR, public policy, market access, med ed, marketing, branding and digital services in a unified offering serving Europe, according to InPharm.

More... »

Cenduit: Now with Patient Reminders

Ignite Health acquires Syndicated Methods

Monday, August 22, 2011 12:15 PM

Ignite Health, an inVentiv Health company, has acquired Syndicated Methods, a San Diego-based mobile development firm. The acquisition rapidly expands Ignite Health's digital leadership into the exploding mobile health space.

More... »

CRF Health – eCOA Forum

PRA on the block, too?

Monday, August 8, 2011 08:02 AM

There was much hoopla made about PPD possibly being for sale after the Wall Street Journal published a story saying as much in mid-July. But what about its smaller competitor, PRA International?

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

inVentiv Health completes PharmaNet acquisition

Thursday, July 14, 2011 12:56 PM

Burlington, Mass.-based inVentiv Health, which offering clinical, commercial and consulting services to the healthcare industry, has completed the acquisition of CRO PharmaNet Development Group. Financial terms of the transaction were not disclosed.

More... »

Ignite Health names Lefkowitz chief creative officer

Wednesday, July 13, 2011 10:19 AM

Ignite Health, an inVentiv Health company, has named Brian Lefkowitz its chief creative officer. Lefkowitz will be responsible for leading all creative efforts as well as building a unified creative structure for the agency's East and West coast offices.

More... »

inVentiv Health completes i3 acquisition

Monday, June 13, 2011 09:56 AM

inVentiv Health has completed the acquisition of CRO i3. i3, previously owned by Ingenix, a UnitedHealth Group company.

More... »

CRO consolidation craze continues as inVentiv scoops up PharmaNet, propelling it into top tier

Monday, May 23, 2011 08:40 AM

The Pac Man game continues, with mid-tier CROs being acquired or buying one another on an almost weekly basis.

More... »

inVentiv Health to acquire PharmaNet

Tuesday, May 17, 2011 10:54 AM

InVentiv Health, a service provider to the healthcare industry, has signed a definitive agreement to purchase CRO PharmaNet Development Group. Financial terms of the transaction were not disclosed.

More... »

inVentiv Health buys i3 divisions, Campbell Alliance, allowing it to compete with CRO industry’s big players

Monday, January 31, 2011 08:00 AM

Ingenix, a UnitedHealth Group subsidiary that provides health care information to the managed care and drug development sectors, is selling off its clinical trial management and contract research services. Those holdings include i3 Research, i3 Statprobe and i3 Pharma Resourcing. 

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs